Compare Heron Therapeutics Inc (HRTX) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Schlumberger NV — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Schlumberger NV trades at $49 (market cap $71.18B). The key difference: Schlumberger NV is far larger — about 961.4× Heron Therapeutics Inc's market cap, and Schlumberger NV pays a 2.46% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Schlumberger NV for 99 Days on average.
| HRTX | SLB | |
|---|---|---|
Market Cap | $74.04M | $71.18B |
Volume | 3,668,095 | 14,872,321 |
Sector | Health | Energy |
52-Week High | $1.49 | $60.10 |
52-Week Low | $0.27 | $31.72 |
Typical Hold Time | 35 Days | 99 Days |
Enterprise Value | $180.78M | $79.91B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
SLB trades at $48.98, down 2.04% with bearish technical signals despite strong analyst support. The company maintains solid profitability with 8.53% net margin and 13.37% ROE, though recent revenue and earnings show slight contraction. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility and expansion in key energy markets.
Wall Street remains bullish with 85% buy ratings and $64.58 price target implying 32% upside. However, declining profit margins and bearish technical indicators suggest near-term pressure. The stock offers value at current levels for investors comfortable with energy sector volatility and execution risks on new contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
